Merck & Co.
As a leader in biopharmaceuticals, we focus on scientific innovation to deliver medicines and vaccines that may help millions of people around the world.
We’re a global health care company working to deliver innovative health solutions through our medicines, vaccines, biologic therapies and animal health products. We’re focused on discovering new solutions for today and the future.
We aspire to be the premier research-intensive biopharmaceutical company. We’re at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
Explore Careers In
Our Therapeutic Areas:
We hold ourselves to the highest standards of ethics and integrity.
We’re driven by a desire to improve life
Our values represent the core of our character and guide every decision and action we take.
Patients first
Respect for people
Ethics and integrity
Innovation and scientific excellence
Don’t just join a company … find a sense of belonging! Our Employee Business Resource Groups (EBRGs) are voluntary, employee-led groups that aim to foster a diverse, inclusive work environment by supporting career development while providing culturally relevant insights that drive success. These groups and the people in them will provide a warm welcome to you.
Get to know us personally through employee spotlights, blogs and our podcast! Follow us on careers social for interview tips, resume tips, DEI, divisional information and more!
X | Facebook | Instagram | YouTube | Careers Blog | Career On Purpose Podcast
Blog Post
Sherif Chalifa, Business Analyst for Quality Systems
Sherif Chalifa, Business Analyst for Quality Systems
As I reflect on my time since joining Merck earlier this year, I am thrilled to say that it has been an excellent experience thus far.
Our Business
Our Business
Our Business
Make a change
Make a change
How we hire
How we hire
A decade of oncology advancements
A decade of oncology advancements
NEWS
It was a busy week for clinical trial announcements. Here’s a look.
Merck announced that its proposed treatment Keytruda for non-small cell lung cancer delivered positive results from its Phase III trial.
AstraZeneca and Merck announced their Lynparza drug reduced the risk of death by 32% compared to placebo for specific breast cancer patients.
More pharmaceutical companies are joining to put economic pressure on Russia by suspending some or all operations within that country following the invasion of Ukraine.
Imugene announced a clinical trial collaboration and supply deal with Merck, while Merck said it is halting a Keytruda combination trial with AstraZeneca in prostate cancer.
The FDA has a full PDUFA calendar for the second half of March for New Drug Applications and Biologics License Applications. Here’s a look.
The death toll related to COVID-19 is more than 6 million, according to the Johns Hopkins COVID-19 dashboard, but it has long been suspected that the toll is significantly higher.
Pfizer has launched a Phase II/III study to assess its oral antiviral Paxlovid in non-hospitalized symptomatic pediatric patients who are at risk for progression to serious disease.
The FDA clinical hold comes after Alpine reported a patient died during the NEON-2 trial.
JOBS
IN THE PRESS